Tafinlar Oral Capsule 50Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Tafinlar: Oral capsule (50mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

DABRAFENIB (da braf e nib) is used to treat certain types of melanoma, a skin cancer. It targets specific cancer cells and stops the cancer cells from growing.

In-Depth Information

Tafinlar 50mg Capsule

NDC: 001730846
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Malignant Melanoma

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Tafinlar 50mg Capsule

Reported Side Effects for Tafinlar 50mg Capsule

High Blood Pressure Incidence:
<10.0%*
Severity: MODERATE
Onset: EARLY
Blurred Vision Incidence:
<2.0%*
Severity: MODERATE
Onset: EARLY
Low Potassium Levels Incidence:
<6.0%*
Severity: SEVERE
Onset: DELAYED
Low Magnesium Levels Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Low Phosphate Level Incidence:
<11.0%*
Severity: SEVERE
Onset: DELAYED
Inability To Sleep Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Inflamed Iris (Eye) Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Weakness Incidence:
<10.0%*
Severity: MILD
Onset: DELAYED
Intestinal Bleeding Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
Eye Pain Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Light Sensitivity Incidence:
<2.0%*
Severity: MODERATE
Onset: EARLY
Mouth Ulcers Incidence:
<10.0%*
Severity: MODERATE
Onset: DELAYED
Low Platelet Count Incidence:
<4.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Pancreas Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
<10.0%*
Severity: MILD
Onset: DELAYED
Anemia Incidence:
<7.0%*
Severity: SEVERE
Onset: DELAYED
Low Albumin In Blood Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Joint Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Kidney Inflammation Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Dehydration Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Bleeding In The Brain Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
<17.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Hair Follicles Incidence:
<10.0%*
Severity: MILD
Onset: DELAYED
Heart Failure Incidence:
<6.0%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
<4.0%*
Severity: SEVERE
Onset: DELAYED
High Calcium Levels Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Excessive Sweating Incidence:
<10.0%*
Severity: MILD
Onset: DELAYED
Blistery Rash Incidence:
<10.0%*
Severity: MODERATE
Onset: EARLY
Chills Incidence:
0.5%*
Severity: SEVERE
Onset: RAPID
Fainting Incidence:
0.7%*
Severity: MILD
Onset: EARLY
Hyperkeratosis Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Eye Inflammation Incidence:
1.0-2.0%*
Severity: SEVERE
Onset: DELAYED
Muscle Cramps Incidence:
2.0-16.0%*
Severity: MILD
Onset: DELAYED
Long Qt Syndrome Incidence:
2.0-4.0%*
Severity: SEVERE
Onset: RAPID
Vomiting Incidence:
2.0-4.0%*
Severity: SEVERE
Onset: EARLY
Back Pain Incidence:
2.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Skin Redness Incidence:
2.0-15.0%*
Severity: MODERATE
Onset: EARLY
Hand And Foot Syndrome Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
2.0-6.0%*
Severity: SEVERE
Onset: EARLY
Constipation Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
2.0-6.0%*
Severity: SEVERE
Onset: EARLY
Stomach Pain Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Headache Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Muscle Pain Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Low White Blood Cells Incidence:
2.0-13.0%*
Severity: SEVERE
Onset: DELAYED
Heart Muscle Disease Incidence:
2.9-6.0%*
Severity: SEVERE
Onset: DELAYED
Fever Incidence:
3.7-5.0%*
Severity: SEVERE
Onset: EARLY
Secondary Malignancy Incidence:
4.0%*
Severity: SEVERE
Onset: DELAYED
Drug-Induced Acne Incidence:
4.0-18.0%*
Severity: MILD
Onset: DELAYED
Low White Blood Cell Counts Incidence:
4.0-5.0%*
Severity: SEVERE
Onset: DELAYED
Increased Blood Sugar Incidence:
4.7-6.0%*
Severity: SEVERE
Onset: DELAYED
Bleeding Incidence:
5.0%*
Severity: SEVERE
Onset: EARLY
Dry Mouth Incidence:
6.0-11.0%*
Severity: MILD
Onset: EARLY
Low Blood Sodium Levels Incidence:
6.0-40.0%*
Severity: MODERATE
Onset: DELAYED
Night Sweats Incidence:
6.0-24.0%*
Severity: MILD
Onset: EARLY
Low Lymphocytes Incidence:
6.0-22.0%*
Severity: SEVERE
Onset: DELAYED
Kidney Failure Incidence:
7.0%*
Severity: SEVERE
Onset: DELAYED
Low Calcium Levels Incidence:
9.0-20.0%*
Severity: MODERATE
Onset: DELAYED
Lightheadedness Incidence:
9.0-16.0%*
Severity: MILD
Onset: EARLY
Sore Throat Incidence:
10.0%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
11.0-13.0%*
Severity: MILD
Onset: RAPID
Cough Incidence:
11.0-29.0%*
Severity: MILD
Onset: DELAYED
High Potassium Level Incidence:
15.0-22.0%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
17.0-53.0%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
17.0-31.0%*
Severity: MODERATE
Onset: DELAYED
Decreased Appetite Incidence:
19.0-30.0%*
Severity: MILD
Onset: DELAYED
Hair Loss Incidence:
22.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Tafinlar 50mg Capsule

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Grapefruit juice and Tafinlar 50mg Capsule(Dabrafenib)
Grapefruit juice and Dabrafenib(Dabrafenib)
If you drink grapefruit juice, talk to your health care professional. Do not take dabrafenib with grapefruit juice because taking these together may result in increased dabrafenib levels in your body and an increased risk of dabrafenib side effects.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Tafinlar

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5